Bristol Myers Squibb BMY announced a strategic collaboration agreement with BioNTech BNTX for the global co-development and ...

These five quality blue-chip stocks should pay a higher dividend than a high-yield money market after Federal Reserve ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its patents for the drug, which is used to treat multiple myeloma, a blood cancer ...

Blue-chip dividend stocks are typically safe, and many are reasonably priced. Five may be incredible ideas for growth and income investors.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse payments to delay cheaper generics of Pomalyst.

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic versions of its blockbuster blood cancer drug Pomalyst off the market so it ...

Cigna (CI) sues Bristol Myers Squibb (BMY), over antitrust violations related to marketing of its multiple myeloma drug, Pomalyst. Read more here.

BMY depends on label expansion of approved drugs and approval of new drugs to stabilize its revenue base as its legacy drugs ...

Bristol Myers (BMY) Squibb won the dismissal of a proposed class action accusing it of fraudulently obtaining patents and filing sham patent law ...